Abstract：
BACKGROUND: Arylsulfatase A (ARSA), a lysosomal enzyme, has been shown to inhibit the aggregation and propagation of α-synuclein (α-syn) through its molecular chaperone function. The relationship between ARSA levels and Parkinson\'s disease (PD) in the Chinese Han population remains controversial, and few quantitative research studies have investigated the relationship between plasma ARSA levels and PD.
OBJECTIVE: The purpose of this study was to investigate the relationships between ARSA levels and cognitive function in PD patients and to evaluate the association of ARSA and α-syn levels with nonmotor symptoms.
METHODS: Enzyme-linked immunosorbent assay (ELISA) was used to measure the plasma ARSA and α-syn levels in 50 healthy controls, 120 PD patients (61 PD patients with no cognitive impairment (PD-NCI) and 59 PD patients with cognitive impairment (PD-CI)). Motor symptoms and nonmotor symptoms (cognitive function, Unified Parkinson\'s Disease Rating Scale (UPDRS) score, depression, anxiety, constipation, olfactory dysfunction, sleep disruption, and other symptoms) were assessed with the relevant scales. The Kruskal-Wallis H test was used for comparison between groups, and Pearson/Spearman analysis was used for correlation analysis.
RESULTS: The plasma ARSA concentrations were lower in the PD-CI group than in the PD-NCI group. The plasma α-syn levels in the PD-CI group were higher than those in the healthy control group, and the plasma ARSA levels were correlated with the Mini-Mental State Examination (MMSE scores) and Hoehn and Yahr (H-Y) stage.
CONCLUSIONS: We used a quantitative assessment method to show that low plasma ARSA levels and high α-syn levels are related to cognitive impairment in PD patients. Plasma ARSA levels gradually decrease with PD progression.
OBJECTIVE: The purpose of this study was to investigate the relationships between ARSA levels and cognitive function in PD patients and to evaluate the association of ARSA and α-syn levels with nonmotor symptoms.
METHODS: Enzyme-linked immunosorbent assay (ELISA) was used to measure the plasma ARSA and α-syn levels in 50 healthy controls, 120 PD patients (61 PD patients with no cognitive impairment (PD-NCI) and 59 PD patients with cognitive impairment (PD-CI)). Motor symptoms and nonmotor symptoms (cognitive function, Unified Parkinson\'s Disease Rating Scale (UPDRS) score, depression, anxiety, constipation, olfactory dysfunction, sleep disruption, and other symptoms) were assessed with the relevant scales. The Kruskal-Wallis H test was used for comparison between groups, and Pearson/Spearman analysis was used for correlation analysis.
RESULTS: The plasma ARSA concentrations were lower in the PD-CI group than in the PD-NCI group. The plasma α-syn levels in the PD-CI group were higher than those in the healthy control group, and the plasma ARSA levels were correlated with the Mini-Mental State Examination (MMSE scores) and Hoehn and Yahr (H-Y) stage.
CONCLUSIONS: We used a quantitative assessment method to show that low plasma ARSA levels and high α-syn levels are related to cognitive impairment in PD patients. Plasma ARSA levels gradually decrease with PD progression.
摘要：
背景：芳基硫酸酯酶A（ARSA），溶酶体酶，已显示通过其分子伴侣功能抑制α-突触核蛋白（α-syn）的聚集和繁殖。中国汉族人群ARSA水平与帕金森病（PD）的关系仍存在争议，很少有定量研究调查血浆ARSA水平与PD之间的关系。
目的：本研究的目的是探讨PD患者ARSA水平与认知功能之间的关系，并评估ARSA和α-syn水平与非运动症状的关系。
方法：采用酶联免疫吸附试验（ELISA）测定50例健康对照者血浆ARSA和α-syn水平，120例PD患者（61例无认知障碍的PD患者（PD-NCI）和59例有认知障碍的PD患者（PD-CI））。运动症状和非运动症状(认知功能，统一帕金森病评定量表（UPDRS）评分，抑郁症,焦虑,便秘,嗅觉功能障碍,睡眠中断，和其他症状）用相关量表进行评估。Kruskal-WallisH检验用于组间比较，相关分析采用Pearson/Spearman分析。
结果：PD-CI组血浆ARSA浓度低于PD-NCI组。PD-CI组血浆α-syn水平高于健康对照组,血浆ARSA水平与简易精神状态检查（MMSE评分）以及Hoehn和Yahr（H-Y）阶段相关。
结论：我们使用定量评估方法显示，血浆ARSA水平低和α-syn水平高与PD患者的认知障碍有关。血浆ARSA水平随着PD进展逐渐降低。
目的：本研究的目的是探讨PD患者ARSA水平与认知功能之间的关系，并评估ARSA和α-syn水平与非运动症状的关系。
方法：采用酶联免疫吸附试验（ELISA）测定50例健康对照者血浆ARSA和α-syn水平，120例PD患者（61例无认知障碍的PD患者（PD-NCI）和59例有认知障碍的PD患者（PD-CI））。运动症状和非运动症状(认知功能，统一帕金森病评定量表（UPDRS）评分，抑郁症,焦虑,便秘,嗅觉功能障碍,睡眠中断，和其他症状）用相关量表进行评估。Kruskal-WallisH检验用于组间比较，相关分析采用Pearson/Spearman分析。
结果：PD-CI组血浆ARSA浓度低于PD-NCI组。PD-CI组血浆α-syn水平高于健康对照组,血浆ARSA水平与简易精神状态检查（MMSE评分）以及Hoehn和Yahr（H-Y）阶段相关。
结论：我们使用定量评估方法显示，血浆ARSA水平低和α-syn水平高与PD患者的认知障碍有关。血浆ARSA水平随着PD进展逐渐降低。
